MicroRNA-152 Acts as a Tumor Suppressor MicroRNA by Inhibiting Kruppel-Like Factor 5 in Human Cervical Cancer

被引:18
作者
Zhang, Haiyan [1 ,2 ]
Lu, Yanxia [3 ]
Wang, Surong [3 ]
Sheng, Xiugui [4 ]
Zhang, Shiqian [1 ]
机构
[1] Shandong Univ, Dept Gynecol, Affiliated Qilu Hosp, 127 West Cultural Rd, Jinan 250012, Shandong, Peoples R China
[2] Linyi Peoples Hosp, Dept Gynecol Ward 1, Linyi, Shandong, Peoples R China
[3] Linyi Peoples Hosp, Dept Gynecol Ward 3, Linyi, Shandong, Peoples R China
[4] Chinese Acad Med Sci, Canc Hosp, Dept Gynecol, Beijing, Peoples R China
关键词
miR-152; Cervical cancer (CC); Kruppel-like factor 5 (KLF5); Proliferation; Cell cycle; HUMAN-PAPILLOMAVIRUS; PROLIFERATION; MIR-152; EXPRESSION;
D O I
10.3727/096504018X15252202178408
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aberrant expression of microRNA-152 (miR-152) is frequently observed in human cancers including ovarian cancer, breast cancer, prostate cancer, and gastric cancer. However, its expression and functional role in cervical cancer (CC) are poorly understood. Also, the association between miR-152 and Kruppel-like factor 5 (KLF5) expression in CC remains unclear. In this study, analyzing the expression of miR-152 by quantitative real-time PCR (qRT-PCR) revealed it was sharply reduced in CC tissues and cell lines. In addition, the negative correlation of miR-152 expression and KLF5 expression was observed. The dual-luciferase reporter assay validated that KLF5 was a target of miR-152. In vitro functional assays revealed that miR-152 could inhibit cell proliferation and cell cycle progression through regulating the expression of KLF5. Taken together, our study suggested that miR-152 functions as a tumor suppressor in CC, and the miR-152/KLF5 axis may provide novel therapeutic targets for CC treatment.
引用
收藏
页码:335 / 340
页数:6
相关论文
共 23 条
[1]  
Appleby P, 2007, LANCET, V370, P1609, DOI 10.1016/S0140-6736(07)61684-5
[2]   MicroRNAs in endometrial cancer [J].
Banno, Kouji ;
Yanokura, Megumi ;
Kisu, Iori ;
Yamagami, Wataru ;
Susumu, Nobuyuki ;
Aoki, Daisuke .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (02) :186-192
[3]   Pembrolizumab in cervical cancer: latest evidence and clinical usefulness [J].
Borcoman, Edith ;
Le Tourneau, Christophe .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (06) :431-439
[4]   Oncomirs - microRNAs with a role in cancer [J].
Esquela-Kerscher, A ;
Slack, FJ .
NATURE REVIEWS CANCER, 2006, 6 (04) :259-269
[5]   Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [J].
Ferlay, Jacques ;
Shin, Hai-Rim ;
Bray, Freddie ;
Forman, David ;
Mathers, Colin ;
Parkin, Donald Maxwell .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) :2893-2917
[6]   Organoid development in cancer genome discovery [J].
Gao, Dong ;
Chen, Yu .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2015, 30 :42-48
[7]  
Gocze K, 2013, ANTICANCER RES, V33, P2561
[8]   Hallmarks of Cancer: The Next Generation [J].
Hanahan, Douglas ;
Weinberg, Robert A. .
CELL, 2011, 144 (05) :646-674
[9]   Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world [J].
Kamangar, Farin ;
Dores, Graca M. ;
Anderson, William F. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (14) :2137-2150
[10]   miR-152 is involved in the proliferation and metastasis of ovarian cancer through repression of ERBB3 [J].
Li, Lian-Wei ;
Xiao, Hong-Qi ;
Ma, Rong ;
Yang, Meng ;
Li, Wan ;
Lou, Ge .
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2018, 41 (03) :1529-1535